-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TIN-816 in Sepsis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TIN-816 in Sepsis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TIN-816 in Sepsis Drug Details: TIN-816 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TIN-816 in Acute Renal Failure (ARF) (Acute Kidney Injury)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TIN-816 in Acute Renal Failure (ARF) (Acute Kidney Injury) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TIN-816 in Acute Renal Failure (ARF) (Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isuzinaxib in Acute Renal Failure (ARF) (Acute Kidney Injury)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isuzinaxib in Acute Renal Failure (ARF) (Acute Kidney Injury) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isuzinaxib in Acute Renal Failure (ARF) (Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OCE-205 in Ascites
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OCE-205 in Ascites report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OCE-205 in Ascites Drug Details: OCE-205 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OCE-205 in Hepatorenal Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OCE-205 in Hepatorenal Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OCE-205 in Hepatorenal Syndrome Drug Details: OCE-205 is under development for the...
-
Government & Regulation
Kenya Insurance Industry – Governance, Risk and Compliance
Kenya Insurance Industry Regulation Overview The Insurance Regulatory Authority (IRA) regulates the Kenya insurance industry along with other regulators and supervisors including the International Association of Insurance Supervisors (IAIS), the African Insurance Organization (AIO), and the Association of Kenya Insurers (AKI). The Kenya insurance industry governance regulation research report provides a detailed analysis of the regulations for several insurance types including life, property, motor, and liability. The report also gives insights into recent and upcoming changes in non-admitted insurance regulations,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Larsucosterol Sodium in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Larsucosterol Sodium in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Larsucosterol Sodium in Chronic Kidney Disease (Chronic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Larsucosterol Sodium in Alcoholic Hepatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Larsucosterol Sodium in Alcoholic Hepatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Larsucosterol Sodium in Alcoholic Hepatitis Drug Details: DUR-928 (DV-928) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OCE-205 in Hepatorenal Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OCE-205 in Hepatorenal Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OCE-205 in Hepatorenal Syndrome Drug Details:OCE-205 is under development for the treatment of...
-
Sector Analysis
Acute Renal Failure (ARF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Acute Renal Failure (ARF) Marketed and Pipeline Drugs Report Overview Acute Renal Failure (ARF) or Acute Kidney Injury (AKI) is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. ARF causes a buildup of waste products in the blood and makes it hard for the kidneys to keep the right balance of fluid in your body. ARF can also affect other organs, such as the brain, heart, and lungs. This...